메뉴 건너뛰기




Volumn 1, Issue 1, 2008, Pages 115-127

Pharmacokinetic drug interactions between drugs of abuse and antiretroviral medications: Implications and management for clinical practice

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXYBUTYRIC ACID; ABACAVIR; ALCOHOL; AMYL NITRITE; BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; BUTYL NITRITE; COCAINE; DIDANOSINE; EFAVIRENZ; ISOBUTYL NITRITE; KETAMINE; LAMIVUDINE; METHADONE; METHAMPHETAMINE; MIDAZOLAM; NEVIRAPINE; OPIATE DERIVATIVE; PHENCYCLIDINE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TETRAHYDROCANNABINOL DERIVATIVE; UNINDEXED DRUG; ZIDOVUDINE;

EID: 38349002778     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/17512433.1.1.115     Document Type: Review
Times cited : (18)

References (170)
  • 1
    • 34548499506 scopus 로고    scopus 로고
    • Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: A prospective, randomized, controlled trial
    • Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. Clin. Infect. Dis. 45, 770-778 (2007).
    • (2007) Clin. Infect. Dis , vol.45 , pp. 770-778
    • Altice, F.L.1    Maru, D.S.2    Bruce, R.D.3    Springer, S.A.4    Friedland, G.H.5
  • 2
    • 34250831611 scopus 로고    scopus 로고
    • A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users
    • Macalino GE, Hogan JW, Mitty JA et al. A randomized clinical trial of community-based directly observed therapy as an adherence intervention for HAART among substance users. AIDS 21, 1473-1477 (2007).
    • (2007) AIDS , vol.21 , pp. 1473-1477
    • Macalino, G.E.1    Hogan, J.W.2    Mitty, J.A.3
  • 3
    • 0242552872 scopus 로고    scopus 로고
    • Importance of P-glycoprotein for drug disposition in humans
    • Fromm MF. Importance of P-glycoprotein for drug disposition in humans. Eur. J. Clin. Invest. 33 (Suppl. 2), 6-9 (2003).
    • (2003) Eur. J. Clin. Invest , vol.33 , Issue.SUPPL. 2 , pp. 6-9
    • Fromm, M.F.1
  • 4
    • 0342762062 scopus 로고    scopus 로고
    • The barrier function of CYP3A4 and P-glycoprotein in the small bowel
    • Watkins PB. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv. Drug Deliv. Rev. 27, 161-170 (1997).
    • (1997) Adv. Drug Deliv. Rev , vol.27 , pp. 161-170
    • Watkins, P.B.1
  • 7
    • 34948854765 scopus 로고    scopus 로고
    • Effects of HIV protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro
    • Tong L, Phan TK, Robinson KL et al. Effects of HIV protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob. Agents Chemother. 51(10), 3498-3504 (2007).
    • (2007) Antimicrob. Agents Chemother , vol.51 , Issue.10 , pp. 3498-3504
    • Tong, L.1    Phan, T.K.2    Robinson, K.L.3
  • 8
    • 3042568988 scopus 로고    scopus 로고
    • Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers
    • Ding R, Tayrouz Y, Riedel KD et al. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin. Pharmacol. Ther. 76, 73-84 (2004).
    • (2004) Clin. Pharmacol. Ther , vol.76 , pp. 73-84
    • Ding, R.1    Tayrouz, Y.2    Riedel, K.D.3
  • 9
    • 0036893374 scopus 로고    scopus 로고
    • Inhibition and active sites of UDP-glucuronosyltransferases 2B7 and 1A1
    • Rios GR, Tephly TR. Inhibition and active sites of UDP-glucuronosyltransferases 2B7 and 1A1. Drug Metab. Dispos. 30, 1364-1367 (2002).
    • (2002) Drug Metab. Dispos , vol.30 , pp. 1364-1367
    • Rios, G.R.1    Tephly, T.R.2
  • 10
    • 33845366857 scopus 로고    scopus 로고
    • Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals
    • Markowitz M, Morales-Ramirez JO, Nguyen BY et al. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J. Acquir. Immune Defic. Syndr. 43, 509-515 (2006).
    • (2006) J. Acquir. Immune Defic. Syndr , vol.43 , pp. 509-515
    • Markowitz, M.1    Morales-Ramirez, J.O.2    Nguyen, B.Y.3
  • 13
    • 34147136222 scopus 로고    scopus 로고
    • Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: A Phase II randomised controlled trial
    • Grinsztejn B, Nguyen BY, Katlama C et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a Phase II randomised controlled trial. Lancet 369, 1261-1269 (2007).
    • (2007) Lancet , vol.369 , pp. 1261-1269
    • Grinsztejn, B.1    Nguyen, B.Y.2    Katlama, C.3
  • 14
    • 0034638766 scopus 로고    scopus 로고
    • Pharmacogenetics and adverse drug reactions
    • Meyer UA. Pharmacogenetics and adverse drug reactions. Lancet 356, 1667-1671 (2000).
    • (2000) Lancet , vol.356 , pp. 1667-1671
    • Meyer, U.A.1
  • 15
    • 3142630463 scopus 로고    scopus 로고
    • Cellular nucleoside pharmacokinetics and pharmacology: A potentially important determinant of antiretroviral efficacy
    • Sommadossi JP. Cellular nucleoside pharmacokinetics and pharmacology: a potentially important determinant of antiretroviral efficacy. AIDS 12(Suppl. 3), S1-S8 (1998).
    • (1998) AIDS , vol.12 , Issue.SUPPL. 3
    • Sommadossi, J.P.1
  • 16
    • 0031929218 scopus 로고    scopus 로고
    • Chemotherapeutic agents for human immunodeficiency virus infection: Mechanism of action, pharmacokinetics, metabolism, and adverse reactions
    • Beach JW. Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions. Clin. Ther. 20, 2-25 (1998).
    • (1998) Clin. Ther , vol.20 , pp. 2-25
    • Beach, J.W.1
  • 18
    • 0029591968 scopus 로고
    • Metabolism of zidovudine
    • Veal GJ, Back DJ. Metabolism of zidovudine. Gen. Pharmacol. 26, 1469-1475 (1995).
    • (1995) Gen. Pharmacol , vol.26 , pp. 1469-1475
    • Veal, G.J.1    Back, D.J.2
  • 19
    • 0031710248 scopus 로고    scopus 로고
    • Safety; pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl] adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults
    • Decks SG, Barditch-Crovo P, Lietman PS et al. Safety; pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl] adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob. Agents Chemother. 42, 2380-2384 (1998).
    • (1998) Antimicrob. Agents Chemother , vol.42 , pp. 2380-2384
    • Decks, S.G.1    Barditch-Crovo, P.2    Lietman, P.S.3
  • 20
    • 0002343528 scopus 로고    scopus 로고
    • Antiviral agents
    • 9th Edition, Katzung BG Ed, The McGraw-Hill Companies, Inc, Columbus, OH, USA
    • Safrin S. Antiviral agents. In: Basic & Clinical Pharmacology (9th Edition). Katzung BG (Ed.). The McGraw-Hill Companies, Inc., Columbus, OH, USA (2004).
    • (2004) Basic & Clinical Pharmacology
    • Safrin, S.1
  • 23
    • 0037256015 scopus 로고    scopus 로고
    • Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection
    • Csajka C, Marzolini C, Fattinger K et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin. Pharmacol. Ther. 73, 20-30 (2003).
    • (2003) Clin. Pharmacol. Ther , vol.73 , pp. 20-30
    • Csajka, C.1    Marzolini, C.2    Fattinger, K.3
  • 24
    • 0035875828 scopus 로고    scopus 로고
    • Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
    • Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15, 71-75 (2001).
    • (2001) AIDS , vol.15 , pp. 71-75
    • Marzolini, C.1    Telenti, A.2    Decosterd, L.A.3    Greub, G.4    Biollaz, J.5    Buclin, T.6
  • 25
    • 0343911677 scopus 로고    scopus 로고
    • Nevirapine, a nonnucleoside reverse transcriptase inhibitor: Metabolism in man, mouse, rat, dog, cynomolgus monkey and chimpanzee
    • Presented at:, Vancouver, BC, Canada, 7-12 July
    • Riska P, Erickson D, Joseph D et al. Nevirapine, a nonnucleoside reverse transcriptase inhibitor: metabolism in man, mouse, rat, dog, cynomolgus monkey and chimpanzee. Presented at: XI International Conference on AIDS. Vancouver, BC, Canada, 7-12 July 1996.
    • (1996) XI International Conference on AIDS
    • Riska, P.1    Erickson, D.2    Joseph, D.3
  • 26
    • 0003683804 scopus 로고    scopus 로고
    • DuPont Pharmaceuticals, Wilmington, DE, USA
    • Sustiva. Product information. DuPont Pharmaceuticals, Wilmington, DE, USA (1998).
    • (1998) Product information
    • Sustiva1
  • 27
    • 21544472342 scopus 로고    scopus 로고
    • Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: Results of AIDS Clinical Trials Group 5108 Study
    • Gerber JG, Rosenkranz SL, Fichtenbaum CJ et al. Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study. J. Acquir. Immune Defic. Syndr. 39(3), 307-312 (2005).
    • (2005) J. Acquir. Immune Defic. Syndr , vol.39 , Issue.3 , pp. 307-312
    • Gerber, J.G.1    Rosenkranz, S.L.2    Fichtenbaum, C.J.3
  • 28
    • 0035058665 scopus 로고    scopus 로고
    • Delavirdine: Clinical pharmacokinetics and drug interactions
    • Tran JQ, Gerber JG, Kerr BM. Delavirdine: clinical pharmacokinetics and drug interactions. Clin. Pharmacokinet. 40, 207-226 (2001).
    • (2001) Clin. Pharmacokinet , vol.40 , pp. 207-226
    • Tran, J.Q.1    Gerber, J.G.2    Kerr, B.M.3
  • 30
    • 0032580479 scopus 로고    scopus 로고
    • HIV-protease inhibitors
    • Flexner C. HIV-protease inhibitors. N. Engl. J. Med. 338, 1281-1292 (1998).
    • (1998) N. Engl. J. Med , vol.338 , pp. 1281-1292
    • Flexner, C.1
  • 32
    • 38349000133 scopus 로고    scopus 로고
    • Prezista™, product information, darunavir. Tibotec Therapeutics, Raritan, NJ, USA (2006).
    • Prezista™, product information, darunavir. Tibotec Therapeutics, Raritan, NJ, USA (2006).
  • 33
    • 0141458274 scopus 로고    scopus 로고
    • Tipranavir: A protease inhibitor from a new class with distinct antiviral activity
    • Yeni P. Tipranavir: a protease inhibitor from a new class with distinct antiviral activity J. Acquir. Immune Defic. Syndr. 34(Suppl. 1), S91-S94 (2003).
    • (2003) J. Acquir. Immune Defic. Syndr , vol.34 , Issue.SUPPL. 1
    • Yeni, P.1
  • 34
    • 0004304575 scopus 로고
    • Vancouver: Applied Therapeutics, Inc
    • Hansten PD. Drug Interactions. Vancouver: Applied Therapeutics, Inc.; (1995).
    • (1995) Drug Interactions
    • Hansten, P.D.1
  • 35
    • 0242380247 scopus 로고    scopus 로고
    • Drug interactions associated with HAART: Focus on treatments for addiction and recreational drugs
    • Faragon JJ, Piliero PJ. Drug interactions associated with HAART: focus on treatments for addiction and recreational drugs. AIDS Read. 13, 433-434 (2003).
    • (2003) AIDS Read , vol.13 , pp. 433-434
    • Faragon, J.J.1    Piliero, P.J.2
  • 36
    • 34249814621 scopus 로고    scopus 로고
    • Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir
    • Vourvahis M, Kashuba AD. Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir. Pharmacotherapy 27, 888-909 (2007).
    • (2007) Pharmacotherapy , vol.27 , pp. 888-909
    • Vourvahis, M.1    Kashuba, A.D.2
  • 37
    • 27544468948 scopus 로고    scopus 로고
    • In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation
    • Zhang D, Chando TJ, Everett DW, Patten CJ, Dehal SS, Humphreys WG. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab. Dispos. 33, 1729-1739 (2005).
    • (2005) Drug Metab. Dispos , vol.33 , pp. 1729-1739
    • Zhang, D.1    Chando, T.J.2    Everett, D.W.3    Patten, C.J.4    Dehal, S.S.5    Humphreys, W.G.6
  • 38
    • 33751005307 scopus 로고    scopus 로고
    • Gilbert's disease and atazanavir: From phenotype to UDP-glucuronosyltransferase haplotype
    • Lankisch TO, Moebius U, Wehmeier M et al. Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype. Hepatology 44, 1324-1332 (2006).
    • (2006) Hepatology , vol.44 , pp. 1324-1332
    • Lankisch, T.O.1    Moebius, U.2    Wehmeier, M.3
  • 39
    • 27644510382 scopus 로고    scopus 로고
    • Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity
    • Dorr P, Westby M, Dobbs S et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49, 4721-4732 (2005).
    • (2005) Antimicrob. Agents Chemother , vol.49 , pp. 4721-4732
    • Dorr, P.1    Westby, M.2    Dobbs, S.3
  • 40
    • 27744548649 scopus 로고    scopus 로고
    • The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS
    • Wood A, Armour D. The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS. Prog. Med. Chem. 43, 239-271 (2005).
    • (2005) Prog. Med. Chem , vol.43 , pp. 239-271
    • Wood, A.1    Armour, D.2
  • 41
    • 3543092371 scopus 로고    scopus 로고
    • The effect of CYP3A4 inhibitors on the pharmacokinetics of CCR5 antagonist UK-427,857 in healthy volunteers
    • Presented at:, Rome, Italy, 1-3 April
    • Abel S et al. The effect of CYP3A4 inhibitors on the pharmacokinetics of CCR5 antagonist UK-427,857 in healthy volunteers. Presented at: 5th International Workshop on Clinical Pharmacology of HIV Therapy. Rome, Italy, 1-3 April 2004.
    • (2004) 5th International Workshop on Clinical Pharmacology of HIV Therapy
    • Abel, S.1
  • 42
    • 3543092371 scopus 로고    scopus 로고
    • The effect of P450 inducers on the pharmacokinetics of CCR5 antagonist UK-427,857 in healthy volunteers
    • Presented at:, Rome, Italy, 1-3 April
    • Jenkins T, Abel S, Russell D et al. The effect of P450 inducers on the pharmacokinetics of CCR5 antagonist UK-427,857 in healthy volunteers. Presented at: 5th International Workshop on Clinical Pharmacology in HIV Therapy. Rome, Italy, 1-3 April 2004.
    • (2004) 5th International Workshop on Clinical Pharmacology in HIV Therapy
    • Jenkins, T.1    Abel, S.2    Russell, D.3
  • 44
    • 13244288179 scopus 로고    scopus 로고
    • Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide
    • Patel IH, Zhang X, Nieforth K, Salgo M, Buss N. Pharmacokinetics, pharmacodynamics and drug interaction potential of enfuvirtide. Clin. Pharmacokinet. 44, 175-186 (2005).
    • (2005) Clin. Pharmacokinet , vol.44 , pp. 175-186
    • Patel, I.H.1    Zhang, X.2    Nieforth, K.3    Salgo, M.4    Buss, N.5
  • 45
    • 38349024046 scopus 로고    scopus 로고
    • The pharmacology of alcohol
    • 3rd Edition, Graham AW, Schultz TK, Mayo-Smith MF, Ries R Wilford BB Eds, American Society of Addiction Medicine, MD, USA
    • Woodward JJ. The pharmacology of alcohol. In: Principles of Addiction Medicine (3rd Edition). Graham AW, Schultz TK, Mayo-Smith MF, Ries R Wilford BB (Eds). American Society of Addiction Medicine, MD, USA 101-118 (2003).
    • (2003) Principles of Addiction Medicine , pp. 101-118
    • Woodward, J.J.1
  • 46
    • 0033661508 scopus 로고    scopus 로고
    • Cytochromes P450 2A6, 2E1, and 3A and production of protein-aldehyde adducts in the liver of patients with alcoholic and non-alcoholic liver diseases
    • Niemela O, Parkkila S, Juvonen RO, Viitala K, Gelboin HV, Pasanen M. Cytochromes P450 2A6, 2E1, and 3A and production of protein-aldehyde adducts in the liver of patients with alcoholic and non-alcoholic liver diseases. J. Hepatol. 33, 893-901 (2000).
    • (2000) J. Hepatol , vol.33 , pp. 893-901
    • Niemela, O.1    Parkkila, S.2    Juvonen, R.O.3    Viitala, K.4    Gelboin, H.V.5    Pasanen, M.6
  • 47
    • 0034251950 scopus 로고    scopus 로고
    • The alcohol-inducible form of cytochrome P450 (CYP2E1): Role in toxicology and regulation of expression
    • Novak RF, Woodcroft KJ. The alcohol-inducible form of cytochrome P450 (CYP2E1): role in toxicology and regulation of expression. Arch. Pharm. Res. 23, 267-282 (2000).
    • (2000) Arch. Pharm. Res , vol.23 , pp. 267-282
    • Novak, R.F.1    Woodcroft, K.J.2
  • 48
    • 0031962151 scopus 로고    scopus 로고
    • Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis
    • Weltman MD, Farrell GC, Hall P, Ingelman-Sundberg M, Liddle C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology 27, 128-133 (1998).
    • (1998) Hepatology , vol.27 , pp. 128-133
    • Weltman, M.D.1    Farrell, G.C.2    Hall, P.3    Ingelman-Sundberg, M.4    Liddle, C.5
  • 49
    • 0029041637 scopus 로고
    • Induction mechanisms of cytochrome P450 2E1 in liver: Interplay between ethanol treatment and starvation
    • Hu Y, Ingelman-Sundberg M, Lindros KO. Induction mechanisms of cytochrome P450 2E1 in liver: interplay between ethanol treatment and starvation. Biochem. Pharmacol. 50, 155-161 (1995).
    • (1995) Biochem. Pharmacol , vol.50 , pp. 155-161
    • Hu, Y.1    Ingelman-Sundberg, M.2    Lindros, K.O.3
  • 50
    • 0027248652 scopus 로고
    • Induction of cytochrome P450 2E1 during chronic ethanol exposure occurs via transcription of the CYP 2E1 gene when blood alcohol concentrations are high
    • Badger TM, Huang J, Ronis M, Lumpkin CK. Induction of cytochrome P450 2E1 during chronic ethanol exposure occurs via transcription of the CYP 2E1 gene when blood alcohol concentrations are high. Biochem. Biophys. Res. Commun. 190, 780-785 (1993).
    • (1993) Biochem. Biophys. Res. Commun , vol.190 , pp. 780-785
    • Badger, T.M.1    Huang, J.2    Ronis, M.3    Lumpkin, C.K.4
  • 51
    • 0027713235 scopus 로고
    • Cytochrome P450 CYP 2E1 induction during chronic alcohol exposure occurs by a two-step mechanism associated with blood alcohol concentrations in rats
    • Ronis MJ, Huang J, Crouch J et al. Cytochrome P450 CYP 2E1 induction during chronic alcohol exposure occurs by a two-step mechanism associated with blood alcohol concentrations in rats. J. Pharmacol. Exp. Ther. 264, 944-950 (1993).
    • (1993) J. Pharmacol. Exp. Ther , vol.264 , pp. 944-950
    • Ronis, M.J.1    Huang, J.2    Crouch, J.3
  • 52
    • 0032407278 scopus 로고    scopus 로고
    • Respective roles of human cytochrome P-4502E1, 1A2, and 3A4 in the hepatic microsomal ethanol oxidizing system
    • Salmela KS, Kessova IG, Tsyrlov IB, Lieber CS. Respective roles of human cytochrome P-4502E1, 1A2, and 3A4 in the hepatic microsomal ethanol oxidizing system. Alcohol. Clin. Exp. Res. 22, 2125-2132 (1998).
    • (1998) Alcohol. Clin. Exp. Res , vol.22 , pp. 2125-2132
    • Salmela, K.S.1    Kessova, I.G.2    Tsyrlov, I.B.3    Lieber, C.S.4
  • 54
    • 0033376610 scopus 로고    scopus 로고
    • CYP2E1 expression in human lymphocytes from various ethnic populations
    • Raucy JL, Schultz ED, Kearins MC et al. CYP2E1 expression in human lymphocytes from various ethnic populations. Alcohol Clin. Exp. Res. 23, 1868-1874 (1999).
    • (1999) Alcohol Clin. Exp. Res , vol.23 , pp. 1868-1874
    • Raucy, J.L.1    Schultz, E.D.2    Kearins, M.C.3
  • 55
    • 0034045094 scopus 로고    scopus 로고
    • Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults
    • McDowell JA, Chittick GE, Stevens CP, Edwards KD, Stein DS. Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human immunodeficiency virus-infected adults. Antimicrob. Agents Chemother. 44, 1686-1690 (2000).
    • (2000) Antimicrob. Agents Chemother , vol.44 , pp. 1686-1690
    • McDowell, J.A.1    Chittick, G.E.2    Stevens, C.P.3    Edwards, K.D.4    Stein, D.S.5
  • 57
    • 34547751005 scopus 로고    scopus 로고
    • Are disulfiram-like reactions associated with abacavir-containing antiretroviral regimens in clinical practice?
    • Barber TJ, Marett B, Waldron S et al. Are disulfiram-like reactions associated with abacavir-containing antiretroviral regimens in clinical practice? AIDS 21, 1823-1824 (2007).
    • (2007) AIDS , vol.21 , pp. 1823-1824
    • Barber, T.J.1    Marett, B.2    Waldron, S.3
  • 58
    • 33847139063 scopus 로고    scopus 로고
    • Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy
    • Pence BW, Miller WC, Gaynes BN, Eron JJ Jr. Psychiatric illness and virologic response in patients initiating highly active antiretroviral therapy. J. Acquit. Immune Defic. Syndr. 44, 159-166 (2007).
    • (2007) J. Acquit. Immune Defic. Syndr , vol.44 , pp. 159-166
    • Pence, B.W.1    Miller, W.C.2    Gaynes, B.N.3    Eron Jr., J.J.4
  • 59
    • 33744902864 scopus 로고    scopus 로고
    • Drug use patterns and adherence to treatment among HIV-positive patients: Evidence from a large sampie of French outpatients (ANRS-EN12-VESPA 2003)
    • Peretti-Watel P, Spire B, Lert F, Obadia Y. Drug use patterns and adherence to treatment among HIV-positive patients: evidence from a large sampie of French outpatients (ANRS-EN12-VESPA 2003). Drug Alcohol Depend. 82(Suppl. 1), S71-S79 (2006).
    • (2006) Drug Alcohol Depend , vol.82 , Issue.SUPPL. 1
    • Peretti-Watel, P.1    Spire, B.2    Lert, F.3    Obadia, Y.4
  • 60
    • 0018761989 scopus 로고
    • The volatile nitrites
    • Cohen S. The volatile nitrites. JAMA 241, 2077-2078 (1979).
    • (1979) JAMA , vol.241 , pp. 2077-2078
    • Cohen, S.1
  • 61
    • 0023973267 scopus 로고
    • Health hazards of nitrite inhalants
    • Haverkos HW, Dougherty J. Health hazards of nitrite inhalants. Am. J. Med. 84, 479-482 (1988).
    • (1988) Am. J. Med , vol.84 , pp. 479-482
    • Haverkos, H.W.1    Dougherty, J.2
  • 62
    • 0034209928 scopus 로고    scopus 로고
    • Very young gay and bisexual men are at risk for HIV infection: The San Francisco Bay Area Young Men's Survey II
    • Waldo CR, McFarland W, Katz MH, MacKellar D, Valleroy LA. Very young gay and bisexual men are at risk for HIV infection: the San Francisco Bay Area Young Men's Survey II. J. Acquir. Immune Defic. Syndr. 24, 168-174 (2000).
    • (2000) J. Acquir. Immune Defic. Syndr , vol.24 , pp. 168-174
    • Waldo, C.R.1    McFarland, W.2    Katz, M.H.3    MacKellar, D.4    Valleroy, L.A.5
  • 63
    • 33749685329 scopus 로고    scopus 로고
    • Substance use and sexual behaviours of Japanese men who have sex with men: A nationwide internet survey conducted in Japan
    • Hidaka Y, Ichikawa S, Koyano J et al. Substance use and sexual behaviours of Japanese men who have sex with men: a nationwide internet survey conducted in Japan. BMC Public Health 6, 239 (2006).
    • (2006) BMC Public Health , vol.6 , pp. 239
    • Hidaka, Y.1    Ichikawa, S.2    Koyano, J.3
  • 64
    • 33645929084 scopus 로고    scopus 로고
    • Unsafe sexual behavior and correlates of risk in a probability sample of men who have sex with men in the era of highly active antiretroviral therapy
    • Brewer DD, Golden MR, Handsfield HH. Unsafe sexual behavior and correlates of risk in a probability sample of men who have sex with men in the era of highly active antiretroviral therapy. Sex. Transm. Dis. 33, 250-255 (2006).
    • (2006) Sex. Transm. Dis , vol.33 , pp. 250-255
    • Brewer, D.D.1    Golden, M.R.2    Handsfield, H.H.3
  • 65
    • 22244447089 scopus 로고    scopus 로고
    • Recreational use and misuse of phosphodiesterase 5 inhibitors
    • Smith KM, Romanelli F. Recreational use and misuse of phosphodiesterase 5 inhibitors. J. Am. Pharm. Acsoc. 45, 63-72 (2005).
    • (2005) J. Am. Pharm. Acsoc , vol.45 , pp. 63-72
    • Smith, K.M.1    Romanelli, F.2
  • 66
    • 18744399306 scopus 로고    scopus 로고
    • Med-psych drug-drug interactions update. Antiretrovirals, part III: Antiretrovirals and drugs of abuse
    • Wynn GH, Cozza KL, Zapor MJ, Wortmann GW, Armstrong SC. Med-psych drug-drug interactions update. Antiretrovirals, part III: antiretrovirals and drugs of abuse. Psychosomatics 46, 79-87 (2005).
    • (2005) Psychosomatics , vol.46 , pp. 79-87
    • Wynn, G.H.1    Cozza, K.L.2    Zapor, M.J.3    Wortmann, G.W.4    Armstrong, S.C.5
  • 67
    • 33750107239 scopus 로고    scopus 로고
    • Denis C, Fatseas M, Lavie E, Auriacombe M. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. Cochrane Database Syst. Rev. 3, CD005194 (2006).
    • Denis C, Fatseas M, Lavie E, Auriacombe M. Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. Cochrane Database Syst. Rev. 3, CD005194 (2006).
  • 68
    • 0033972441 scopus 로고    scopus 로고
    • Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition
    • Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin. Pharmacokinet. 38, 41-57 (2000).
    • (2000) Clin. Pharmacokinet , vol.38 , pp. 41-57
    • Dresser, G.K.1    Spence, J.D.2    Bailey, D.G.3
  • 69
    • 0033323791 scopus 로고    scopus 로고
    • Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triszolam
    • Yuan R, Flockhart DA, Balian JD. Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triszolam. J. Clin. Pharmacol. 39, 1109-1125 (1999).
    • (1999) J. Clin. Pharmacol , vol.39 , pp. 1109-1125
    • Yuan, R.1    Flockhart, D.A.2    Balian, J.D.3
  • 70
    • 33846461184 scopus 로고    scopus 로고
    • Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers
    • Allqvist A, Miura J, Bertilsson L, Mirghani RA. Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers. Eur. J. Clin. Pharmacol. 63, 173-179 (2007).
    • (2007) Eur. J. Clin. Pharmacol , vol.63 , pp. 173-179
    • Allqvist, A.1    Miura, J.2    Bertilsson, L.3    Mirghani, R.A.4
  • 71
    • 0032789533 scopus 로고    scopus 로고
    • Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: The clinical dilemma of concurrent inhibition and induction
    • Greenblatt DJ, von Moltke LL, Daily JP, Harmatz JS, Shader RI. Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction. J. Clin. Psychopharmacol. 19, 293-296 (1999).
    • (1999) J. Clin. Psychopharmacol , vol.19 , pp. 293-296
    • Greenblatt, D.J.1    von Moltke, L.L.2    Daily, J.P.3    Harmatz, J.S.4    Shader, R.I.5
  • 72
    • 0034056369 scopus 로고    scopus 로고
    • Alprazolam-ritonavir interaction: Implications for product labeling
    • Greenblatt DJ, von Moltke LL, Harmatz JS et al. Alprazolam-ritonavir interaction: implications for product labeling. Clin. Pharmacol. Ther. 67, 335-341 (2000).
    • (2000) Clin. Pharmacol. Ther , vol.67 , pp. 335-341
    • Greenblatt, D.J.1    von Moltke, L.L.2    Harmatz, J.S.3
  • 73
    • 0002114783 scopus 로고    scopus 로고
    • Effect of ritonavir on the pharmacokinetics and pharmacodynamics of alprazolam
    • Presented at:, Toronto, ON, Canada, 28 September-1 October
    • Frye R, Bertz R, Granneman GR et al. Effect of ritonavir on the pharmacokinetics and pharmacodynamics of alprazolam. Presented at: 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, ON, Canada, 28 September-1 October 1997.
    • (1997) 37th Interscience Conference on Antimicrobial Agents and Chemotherapy
    • Frye, R.1    Bertz, R.2    Granneman, G.R.3
  • 74
    • 0031032476 scopus 로고    scopus 로고
    • Saquinavir interaction with midazolam: Pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV disease
    • Merry C, Mulcahy F, Barry M, Gibbons S, Back D. Saquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV disease. AIDS 11, 268-269 (1997).
    • (1997) AIDS , vol.11 , pp. 268-269
    • Merry, C.1    Mulcahy, F.2    Barry, M.3    Gibbons, S.4    Back, D.5
  • 75
    • 0032807936 scopus 로고    scopus 로고
    • Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam
    • Palkama VJ, Ahonen J, Neuvonen PJ, Olkkola KT. Effect of saquinavir on the pharmacokinetics and pharmacodynamics of oral and intravenous midazolam. Clin. Pharmacol. Ther. 66, 33-39 (1999).
    • (1999) Clin. Pharmacol. Ther , vol.66 , pp. 33-39
    • Palkama, V.J.1    Ahonen, J.2    Neuvonen, P.J.3    Olkkola, K.T.4
  • 76
    • 0031751330 scopus 로고    scopus 로고
    • Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. [Erratum appears in Clin. Pharmacokinet. 35(6), 473 (1998)]. Clin. Pharmacokinet. 35, 275-291 (1998).
    • Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. [Erratum appears in Clin. Pharmacokinet. 35(6), 473 (1998)]. Clin. Pharmacokinet. 35, 275-291 (1998).
  • 77
    • 0031939246 scopus 로고    scopus 로고
    • Systemic antifungal agents. Drug interactions of clinical significance
    • Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf. 18, 83-97 (1998).
    • (1998) Drug Saf , vol.18 , pp. 83-97
    • Albengres, E.1    Le Louet, H.2    Tillement, J.P.3
  • 78
    • 25144448034 scopus 로고    scopus 로고
    • Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir
    • Le Tiec C, Barrail A, Goujard C, Taburet AM. Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir. Clin. Pharmacokinet. 44, 1035-1050 (2005).
    • (2005) Clin. Pharmacokinet , vol.44 , pp. 1035-1050
    • Le Tiec, C.1    Barrail, A.2    Goujard, C.3    Taburet, A.M.4
  • 79
    • 20444500240 scopus 로고    scopus 로고
    • Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers
    • Chung JY, Cho JY, Yu KS et al. Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. Clin. Pharmacol. Ther. 77, 486-494 (2005).
    • (2005) Clin. Pharmacol. Ther , vol.77 , pp. 486-494
    • Chung, J.Y.1    Cho, J.Y.2    Yu, K.S.3
  • 80
    • 28844431530 scopus 로고    scopus 로고
    • CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia
    • Inomata S, Nagashima A, Itagaki F et al. CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia. Clin. Pharmacol. Ther. 78, 647-655 (2005).
    • (2005) Clin. Pharmacol. Ther , vol.78 , pp. 647-655
    • Inomata, S.1    Nagashima, A.2    Itagaki, F.3
  • 83
    • 0031784886 scopus 로고    scopus 로고
    • Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7
    • Cheng Z, Rios GR, King CD et al. Glucuronidation of catechol estrogens by expressed human UDP-glucuronosyltransferases (UGTs) 1A1, 1A3, and 2B7. Toxicol. Sci. 45, 52-57 (1998).
    • (1998) Toxicol. Sci , vol.45 , pp. 52-57
    • Cheng, Z.1    Rios, G.R.2    King, C.D.3
  • 84
    • 0029145959 scopus 로고
    • Pharmacokinetics and pharmacodynamics of cocaine
    • Cone EJ. Pharmacokinetics and pharmacodynamics of cocaine. J. Anal. Toxicol. 19, 459-478 (1995).
    • (1995) J. Anal. Toxicol , vol.19 , pp. 459-478
    • Cone, E.J.1
  • 85
    • 0034045128 scopus 로고    scopus 로고
    • Mechanisms of cocaine hydrolysis and metabolism in vitro and in vivo: A clarification
    • Warner A, Norman AB. Mechanisms of cocaine hydrolysis and metabolism in vitro and in vivo: a clarification. Ther. Drug Monit. 22, 266-270 (2000).
    • (2000) Ther. Drug Monit , vol.22 , pp. 266-270
    • Warner, A.1    Norman, A.B.2
  • 86
    • 33748187632 scopus 로고    scopus 로고
    • Toxicokinetics of drugs of abuse: Current knowledge of the isoenzymes involved in the human metabolism of tetrahydrocannabinol, cocaine, heroin, morphine, and codeine
    • Maurer HH, Sauer C, Theobald DS. Toxicokinetics of drugs of abuse: current knowledge of the isoenzymes involved in the human metabolism of tetrahydrocannabinol, cocaine, heroin, morphine, and codeine. Ther. Drug Monit. 28, 447-453 (2006).
    • (2006) Ther. Drug Monit , vol.28 , pp. 447-453
    • Maurer, H.H.1    Sauer, C.2    Theobald, D.S.3
  • 87
    • 32644473384 scopus 로고    scopus 로고
    • The pharmacology of cocaine, amphetamines, and other stimulants
    • Graham AW, Schultz TK, Mayo-Smith MF, Ries R, Wilford BB Eds, American Society of Addiction Medicine, MD, USA
    • Gorelick DA, Cornish JL. The pharmacology of cocaine, amphetamines, and other stimulants. In: Principles of Addiction Medicine. Graham AW, Schultz TK, Mayo-Smith MF, Ries R, Wilford BB (Eds). American Society of Addiction Medicine, MD, USA 157-190 (2003).
    • (2003) Principles of Addiction Medicine , pp. 157-190
    • Gorelick, D.A.1    Cornish, J.L.2
  • 88
  • 89
    • 0038347311 scopus 로고    scopus 로고
    • Cocaethylene metabolism and interaction with cocaine and ethanol: Role of carboxylesterases
    • Laizure SC, Mandrell T, Gades NM, Parker RB. Cocaethylene metabolism and interaction with cocaine and ethanol: role of carboxylesterases. Drug Metab. Dispos. 31, 16-20 (2003).
    • (2003) Drug Metab. Dispos , vol.31 , pp. 16-20
    • Laizure, S.C.1    Mandrell, T.2    Gades, N.M.3    Parker, R.B.4
  • 90
    • 0032555782 scopus 로고    scopus 로고
    • Ethanol does not increase the hepatotoxicity of cocaine in primary rat hepatocyte culture
    • Figliomeni ML, Abdel-Rahman MS. Ethanol does not increase the hepatotoxicity of cocaine in primary rat hepatocyte culture. Toxicology 129, 125-135 (1998).
    • (1998) Toxicology , vol.129 , pp. 125-135
    • Figliomeni, M.L.1    Abdel-Rahman, M.S.2
  • 91
    • 0027372346 scopus 로고
    • Oxygen free radical production mediated by cocaine and its ethanol-derived metabolite, cocaethylene, in rat hepatocytes
    • Boelsterli UA, Wolf A, Goldlin C. Oxygen free radical production mediated by cocaine and its ethanol-derived metabolite, cocaethylene, in rat hepatocytes. Hepatology 18, 1154-1161 (1993).
    • (1993) Hepatology , vol.18 , pp. 1154-1161
    • Boelsterli, U.A.1    Wolf, A.2    Goldlin, C.3
  • 93
    • 0026644552 scopus 로고
    • An overview of cocaethylene, an alcohol-derived, psychoactive, cocaine metabolite
    • Landry MJ. An overview of cocaethylene, an alcohol-derived, psychoactive, cocaine metabolite. J. Psychoactive Drugs 24, 273-276 (1992).
    • (1992) J. Psychoactive Drugs , vol.24 , pp. 273-276
    • Landry, M.J.1
  • 95
    • 34249058387 scopus 로고    scopus 로고
    • The impact of ongoing illicit drug use on methadone adherence in illicit drug users receiving treatment for HIV in a directly observed therapy program
    • Raffa JD, Grebely J, Tossonian H et al. The impact of ongoing illicit drug use on methadone adherence in illicit drug users receiving treatment for HIV in a directly observed therapy program. Drug Alcohol Depend. 89, 306-309 (2007).
    • (2007) Drug Alcohol Depend , vol.89 , pp. 306-309
    • Raffa, J.D.1    Grebely, J.2    Tossonian, H.3
  • 96
    • 33847282357 scopus 로고    scopus 로고
    • Drug use and medication adherence among HIV-1 infected individuals
    • Hinkin CH, Barclay TR, Castellon SA et al. Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav. 11, 185-194 (2007).
    • (2007) AIDS Behav , vol.11 , pp. 185-194
    • Hinkin, C.H.1    Barclay, T.R.2    Castellon, S.A.3
  • 98
    • 33751169355 scopus 로고    scopus 로고
    • Proteomic analysis of the effects of cocaine on the enhancement of HIV-1 replication in normal human aatrocytes (NHA)
    • Reynolds JL, Mahajan SD, Bindukumar B, Sykes D, Schwartz SA, Nair MP. Proteomic analysis of the effects of cocaine on the enhancement of HIV-1 replication in normal human aatrocytes (NHA). Brain Res. 1123, 226-236 (2006).
    • (2006) Brain Res , vol.1123 , pp. 226-236
    • Reynolds, J.L.1    Mahajan, S.D.2    Bindukumar, B.3    Sykes, D.4    Schwartz, S.A.5    Nair, M.P.6
  • 99
    • 33646110490 scopus 로고    scopus 로고
    • Cocaine-induced HIV-1 expression in microglia involves σ-1 receptors and transforming growth factor-β1
    • Gekker G, Hu S, Sheng WS, Rock RB, Lokensgard JR, Peterson PK. Cocaine-induced HIV-1 expression in microglia involves σ-1 receptors and transforming growth factor-β1. Int. Immunopharmacol. 6, 1029-1033 (2006).
    • (2006) Int. Immunopharmacol , vol.6 , pp. 1029-1033
    • Gekker, G.1    Hu, S.2    Sheng, W.S.3    Rock, R.B.4    Lokensgard, J.R.5    Peterson, P.K.6
  • 100
    • 23744514536 scopus 로고    scopus 로고
    • Cocaine increases human immunodeficiency virus type 1 neuroinvasion through remodeling brain microvascular endothelial cells
    • Fiala M, Eshleman AJ, Cashman J et al. Cocaine increases human immunodeficiency virus type 1 neuroinvasion through remodeling brain microvascular endothelial cells. J. Neurovirol. 11, 281-291 (2005).
    • (2005) J. Neurovirol , vol.11 , pp. 281-291
    • Fiala, M.1    Eshleman, A.J.2    Cashman, J.3
  • 101
    • 0033956050 scopus 로고    scopus 로고
    • Cocaine differentially modulates chemokine production by mononuclear cells from normal donors and human immunodeficiency virus type 1-infected patients
    • Nair MP, Chadha KC, Hewitt RG, Mahajan S, Sweet A, Schwartz SA. Cocaine differentially modulates chemokine production by mononuclear cells from normal donors and human immunodeficiency virus type 1-infected patients. Clin. Diag. Lab. Immunol. 7, 96-100 (2000).
    • (2000) Clin. Diag. Lab. Immunol , vol.7 , pp. 96-100
    • Nair, M.P.1    Chadha, K.C.2    Hewitt, R.G.3    Mahajan, S.4    Sweet, A.5    Schwartz, S.A.6
  • 102
    • 0035673018 scopus 로고    scopus 로고
    • Effect of cocaine on chemokine and CCR-5 gene expression by mononuclear cells from normal donors and HIV-1 infected patients
    • Nair MP, Mahajan S, Chadha KC et al. Effect of cocaine on chemokine and CCR-5 gene expression by mononuclear cells from normal donors and HIV-1 infected patients. Adv. Exp. Med. Biol. 493, 235-240 (2001).
    • (2001) Adv. Exp. Med. Biol , vol.493 , pp. 235-240
    • Nair, M.P.1    Mahajan, S.2    Chadha, K.C.3
  • 103
    • 21044443286 scopus 로고    scopus 로고
    • Cocaine modulates dendritic cell-specific C type intercellular adhesion molecule-3-grabbing nonintegrin expression by dendritic cells in HIV-1 patients
    • Nair MP, Mahajan SD, Schwartz SA et al. Cocaine modulates dendritic cell-specific C type intercellular adhesion molecule-3-grabbing nonintegrin expression by dendritic cells in HIV-1 patients. J. Immunol. 174, 6617-6626 (2005).
    • (2005) J. Immunol , vol.174 , pp. 6617-6626
    • Nair, M.P.1    Mahajan, S.D.2    Schwartz, S.A.3
  • 104
    • 0037980186 scopus 로고    scopus 로고
    • Use of club drugs by HIV-seropositive and HIV-seronegative gay and bisexual men
    • Romanelli F, Smith KM, Pomeroy C. Use of club drugs by HIV-seropositive and HIV-seronegative gay and bisexual men. Top. HIV Med. 11, 25-32 (2003).
    • (2003) Top. HIV Med , vol.11 , pp. 25-32
    • Romanelli, F.1    Smith, K.M.2    Pomeroy, C.3
  • 105
    • 0018372970 scopus 로고
    • Dose-dependent pharmacokinetics and hypnotic effects of sodium γ-hydroxybutyrate in the rat
    • Lettieri JT, Fung HL. Dose-dependent pharmacokinetics and hypnotic effects of sodium γ-hydroxybutyrate in the rat. J. Pharmacol. Exp. Ther. 208, 7-11 (1979).
    • (1979) J. Pharmacol. Exp. Ther , vol.208 , pp. 7-11
    • Lettieri, J.T.1    Fung, H.L.2
  • 106
    • 0033547191 scopus 로고    scopus 로고
    • Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and γ-hydroxybutyrate
    • Harrington RD, Woodward JA, Hooton TM, Horn JR. Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and γ-hydroxybutyrate. Arch. Intern. Med. 159, 2221-2224 (1999).
    • (1999) Arch. Intern. Med , vol.159 , pp. 2221-2224
    • Harrington, R.D.1    Woodward, J.A.2    Hooton, T.M.3    Horn, J.R.4
  • 107
    • 0024517165 scopus 로고
    • Ketamine: An update on the first twenty-five years of clinical experience
    • Reich DL, Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Can. J. Anaesth. 36, 186-197 (1989).
    • (1989) Can. J. Anaesth , vol.36 , pp. 186-197
    • Reich, D.L.1    Silvay, G.2
  • 108
    • 0035010954 scopus 로고    scopus 로고
    • Involvement of CYP2B6 in N-demethylation of ketamine in human liver microsomes
    • Yanagihara Y, Kariya S, Ohtani M et al. Involvement of CYP2B6 in N-demethylation of ketamine in human liver microsomes. Drug Metab. Dispos. 29, 887-890 (2001).
    • (2001) Drug Metab. Dispos , vol.29 , pp. 887-890
    • Yanagihara, Y.1    Kariya, S.2    Ohtani, M.3
  • 109
    • 8544279622 scopus 로고    scopus 로고
    • Beyond the K-hole: A 3-year longitudinal investigation of the cognitive and subjective effects of ketamine in recreational users who have substantially reduced their use of the drug
    • Morgan CJ, Monaghan L, Curran HV. Beyond the K-hole: a 3-year longitudinal investigation of the cognitive and subjective effects of ketamine in recreational users who have substantially reduced their use of the drug. Addiction 99, 1450-1461 (2004).
    • (2004) Addiction , vol.99 , pp. 1450-1461
    • Morgan, C.J.1    Monaghan, L.2    Curran, H.V.3
  • 110
    • 33646871323 scopus 로고    scopus 로고
    • Acute toxic effects of 'ecstasy' (MDMA) and related compounds: Overview of pathophysiology and clinical management
    • Hall AP, Henry JA. Acute toxic effects of 'ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management. Br. J. Anaesth. 96, 678-685 (2006).
    • (2006) Br. J. Anaesth , vol.96 , pp. 678-685
    • Hall, A.P.1    Henry, J.A.2
  • 111
    • 2542629618 scopus 로고    scopus 로고
    • Schifano F. A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities. Psychopharmacology (Berl.) 173, 242-248 (2004).
    • Schifano F. A bitter pill. Overview of ecstasy (MDMA, MDA) related fatalities. Psychopharmacology (Berl.) 173, 242-248 (2004).
  • 112
    • 34447122644 scopus 로고    scopus 로고
    • Pharmacogenomics: Challenges and opportunities
    • Roden DM, Altman RB, Benowitz NL et al. Pharmacogenomics: challenges and opportunities. Ann. Intern. Med. 145, 749-757 (2006).
    • (2006) Ann. Intern. Med , vol.145 , pp. 749-757
    • Roden, D.M.1    Altman, R.B.2    Benowitz, N.L.3
  • 113
    • 0031931102 scopus 로고    scopus 로고
    • Protease inhibitors as inhibitors of human cytochromes P450: High risk associated with ritonavir
    • von Moltke LL, Greenblatt DJ, Grassi JM et al. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J. Clin. Pharmacol. 38, 106-111 (1998).
    • (1998) J. Clin. Pharmacol , vol.38 , pp. 106-111
    • von Moltke, L.L.1    Greenblatt, D.J.2    Grassi, J.M.3
  • 114
    • 28844482323 scopus 로고    scopus 로고
    • Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers
    • Aarnoutse RE, Kleinnijenhuis J, Koopmans PP et al. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. Clin. Pharmacol. Ther. 78, 664-674 (2005).
    • (2005) Clin. Pharmacol. Ther , vol.78 , pp. 664-674
    • Aarnoutse, R.E.1    Kleinnijenhuis, J.2    Koopmans, P.P.3
  • 115
    • 0032576351 scopus 로고    scopus 로고
    • Fatal interaction between ritonavir and MDMA
    • Henry JA, Hill IR. Fatal interaction between ritonavir and MDMA. Lancet 352, 1751-1752 (1998).
    • (1998) Lancet , vol.352 , pp. 1751-1752
    • Henry, J.A.1    Hill, I.R.2
  • 116
    • 0026680529 scopus 로고
    • Toxicity and deaths from 3,4-methylenedioxymethamphetamine ('ecstasy')
    • Henry JA, Jeffreys KJ, Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine ('ecstasy'). Lancet 340, 384-387 (1992).
    • (1992) Lancet , vol.340 , pp. 384-387
    • Henry, J.A.1    Jeffreys, K.J.2    Dawling, S.3
  • 118
    • 0030774772 scopus 로고    scopus 로고
    • Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6
    • Lin LY, Di Stefano EW, Schmitz DA et al. Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metab. Dispos. 25, 1059-1064 (1997).
    • (1997) Drug Metab. Dispos , vol.25 , pp. 1059-1064
    • Lin, L.Y.1    Di Stefano, E.W.2    Schmitz, D.A.3
  • 119
    • 0034018678 scopus 로고    scopus 로고
    • Possible fatal interaction between protease inhibitors and methamphetamine
    • Hales G, Roth N, Smith D. Possible fatal interaction between protease inhibitors and methamphetamine. Antivir. Ther. (Lond.) 5, 19 (2000).
    • (2000) Antivir. Ther. (Lond.) , vol.5 , pp. 19
    • Hales, G.1    Roth, N.2    Smith, D.3
  • 120
    • 34249109768 scopus 로고    scopus 로고
    • Progress in understanding basal ganglia dysfunction as a common target for methamphetamine abuse and HIV-1 neurodegeneration
    • Theodore S, Cass WA, Nath A, Maragos WF. Progress in understanding basal ganglia dysfunction as a common target for methamphetamine abuse and HIV-1 neurodegeneration. Curr. HIV Res. 5, 301-313 (2007).
    • (2007) Curr. HIV Res , vol.5 , pp. 301-313
    • Theodore, S.1    Cass, W.A.2    Nath, A.3    Maragos, W.F.4
  • 121
    • 30144437077 scopus 로고    scopus 로고
    • Methamphetamine and human immunodeficiency virus protein Tat synergize to destroy dopaminergic terminals in the rat striatum
    • Theodore S, Cass WA, Maragos WF. Methamphetamine and human immunodeficiency virus protein Tat synergize to destroy dopaminergic terminals in the rat striatum. Neuroscience 137, 925-935 (2006).
    • (2006) Neuroscience , vol.137 , pp. 925-935
    • Theodore, S.1    Cass, W.A.2    Maragos, W.F.3
  • 122
    • 33644835175 scopus 로고    scopus 로고
    • The methamphetamine epidemic: Implications for HIV prevention and treatment
    • 2, 194-199
    • Colfax G, Shoptaw S. The methamphetamine epidemic: implications for HIV prevention and treatment. Curr. HIV/AIDS Rep. 2, 194-199 (2005).
    • (2005) Curr. HIV/AIDS Rep
    • Colfax, G.1    Shoptaw, S.2
  • 123
    • 0345166039 scopus 로고    scopus 로고
    • Methamphetamine abuse as a barrier to HIV medication adherence among gay and bisexual men
    • Reback CJ, Larkins S, Shoptaw S. Methamphetamine abuse as a barrier to HIV medication adherence among gay and bisexual men. AIDS Care 15, 775-785 (2003).
    • (2003) AIDS Care , vol.15 , pp. 775-785
    • Reback, C.J.1    Larkins, S.2    Shoptaw, S.3
  • 124
    • 33645107718 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients
    • Rook EJ, van Ree JM, van den Brink W et al. Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients. Basic Clin. Pharmacol. Toxicol. 98, 86-96 (2006).
    • (2006) Basic Clin. Pharmacol. Toxicol , vol.98 , pp. 86-96
    • Rook, E.J.1    van Ree, J.M.2    van den Brink, W.3
  • 125
    • 14944354806 scopus 로고    scopus 로고
    • Modulation of UDP-glucuronosyltransferase function by cytochrome P450: Evidence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4
    • Takeda S, Ishii Y, Iwanaga M et al. Modulation of UDP-glucuronosyltransferase function by cytochrome P450: evidence for the alteration of UGT2B7-catalyzed glucuronidation of morphine by CYP3A4. Mol. Pharmacol. 67, 665-672 (2005).
    • (2005) Mol. Pharmacol , vol.67 , pp. 665-672
    • Takeda, S.1    Ishii, Y.2    Iwanaga, M.3
  • 126
    • 0038193696 scopus 로고    scopus 로고
    • Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro
    • Wang JS, DeVane CL. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab. Dispos. 31, 742-747 (2003).
    • (2003) Drug Metab. Dispos , vol.31 , pp. 742-747
    • Wang, J.S.1    DeVane, C.L.2
  • 127
    • 0036213788 scopus 로고    scopus 로고
    • Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers
    • Begre S, von Bardeleben U, Ladewig D et al. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J. Clin. Psychopharmacol. 22, 211-215 (2002).
    • (2002) J. Clin. Psychopharmacol , vol.22 , pp. 211-215
    • Begre, S.1    von Bardeleben, U.2    Ladewig, D.3
  • 128
    • 0029944684 scopus 로고    scopus 로고
    • Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes
    • Iribarne C, Berthou F, Baird S et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem. Res. Toxicol. 9, 365-373 (1996).
    • (1996) Chem. Res. Toxicol , vol.9 , pp. 365-373
    • Iribarne, C.1    Berthou, F.2    Baird, S.3
  • 129
    • 0027454958 scopus 로고
    • Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone
    • Wu D, Otton SV, Sproule BA et al. Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone. Br. J. Clin. Pharmacol. 35, 30-34 (1993).
    • (1993) Br. J. Clin. Pharmacol , vol.35 , pp. 30-34
    • Wu, D.1    Otton, S.V.2    Sproule, B.A.3
  • 130
    • 33646776797 scopus 로고    scopus 로고
    • Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: Implications and management for clinical practice
    • Bruce RD, Altice FL, Gourevitch MN, Friedland GH. Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J. Acquir. Immune Defic. Syndr. 41, 563-572 (2006).
    • (2006) J. Acquir. Immune Defic. Syndr , vol.41 , pp. 563-572
    • Bruce, R.D.1    Altice, F.L.2    Gourevitch, M.N.3    Friedland, G.H.4
  • 133
    • 0036190773 scopus 로고    scopus 로고
    • The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects
    • Rainey PM, Friedland GH, Snidow JW et al. The pharmacokinetics of methadone following co-administration with a lamivudine/zidovudine combination tablet in opiate-dependent subjects. Am. J. Addict. 11, 66-74 (2002).
    • (2002) Am. J. Addict , vol.11 , pp. 66-74
    • Rainey, P.M.1    Friedland, G.H.2    Snidow, J.W.3
  • 136
    • 33646785913 scopus 로고    scopus 로고
    • Pharmacokinetics (PK) of didanosine (ddI) from encapsulated enteric coated bead formulation (EC) vs chewable tablet formulation in patients (pts) on chronic methadone therapy
    • Presented at:, Barcelona, Spain, 7-12 July
    • Friedland G, Rainey P, Jatlow P, Andrews L, Damle B, McCance-Katz EF. Pharmacokinetics (PK) of didanosine (ddI) from encapsulated enteric coated bead formulation (EC) vs chewable tablet formulation in patients (pts) on chronic methadone therapy. Presented at: 14th International AIDS Conference. Barcelona, Spain, 7-12 July 2002.
    • (2002) 14th International AIDS Conference
    • Friedland, G.1    Rainey, P.2    Jatlow, P.3    Andrews, L.4    Damle, B.5    McCance-Katz, E.F.6
  • 137
    • 0033044075 scopus 로고    scopus 로고
    • Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone
    • Altice FL, Friedland GH, Cooney EL. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 13, 957-962 (1999).
    • (1999) AIDS , vol.13 , pp. 957-962
    • Altice, F.L.1    Friedland, G.H.2    Cooney, E.L.3
  • 138
    • 0035503197 scopus 로고    scopus 로고
    • Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users
    • Clarke SM, Mulcahy FM, Tjia J et al. Pharmacokinetic interactions of nevirapine and methadone and guidelines for use of nevirapine to treat injection drug users. Clin. Infect. Dis. 33, 1595-1597 (2001).
    • (2001) Clin. Infect. Dis , vol.33 , pp. 1595-1597
    • Clarke, S.M.1    Mulcahy, F.M.2    Tjia, J.3
  • 139
    • 0032957797 scopus 로고    scopus 로고
    • Methadone withdrawal when starting an antiretroviral regimen including nevirapine
    • Heelon MW, Meade LB. Methadone withdrawal when starting an antiretroviral regimen including nevirapine. Pharmacotherapy 19, 471-472 (1999).
    • (1999) Pharmacotherapy , vol.19 , pp. 471-472
    • Heelon, M.W.1    Meade, L.B.2
  • 140
    • 7244226310 scopus 로고    scopus 로고
    • Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients
    • Stocker H, Kruse G, Kreckel P et al. Nevirapine significantly reduces the levels of racemic methadone and (R)-methadone in human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 48, 4148-4153 (2004).
    • (2004) Antimicrob. Agents Chemother , vol.48 , pp. 4148-4153
    • Stocker, H.1    Kruse, G.2    Kreckel, P.3
  • 142
    • 0035034313 scopus 로고    scopus 로고
    • The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz
    • Clarke SM, Mulcahy FM, Tjia J et al. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br. J. Clin. Pharmacol. 51, 213-217 (2001).
    • (2001) Br. J. Clin. Pharmacol , vol.51 , pp. 213-217
    • Clarke, S.M.1    Mulcahy, F.M.2    Tjia, J.3
  • 144
    • 38349046213 scopus 로고    scopus 로고
    • Aptivus®, tipranavir. Product information. Boehringer Ingelheim Pharmaceuticals, Inc., CT, USA (2005).
    • Aptivus®, tipranavir. Product information. Boehringer Ingelheim Pharmaceuticals, Inc., CT, USA (2005).
  • 146
    • 17844409048 scopus 로고    scopus 로고
    • In vitro metabolism study of buprenorphine: Evidence for new metabolic pathways
    • Picard N, Cresteil T, Djebli N, Marquet P. In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab. Dispos. 33, 689-695 (2005).
    • (2005) Drug Metab. Dispos , vol.33 , pp. 689-695
    • Picard, N.1    Cresteil, T.2    Djebli, N.3    Marquet, P.4
  • 147
    • 0030221217 scopus 로고    scopus 로고
    • The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1
    • King CD, Green MD, Rios GR et al. The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1. Arch. Biochem. Biophys. 332, 92-100 (1996).
    • (1996) Arch. Biochem. Biophys , vol.332 , pp. 92-100
    • King, C.D.1    Green, M.D.2    Rios, G.R.3
  • 148
  • 149
    • 0042333489 scopus 로고    scopus 로고
    • Controlled, randomized trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: A novel study
    • Ahmadi J, Ahmadi K, Ohaeri J. Controlled, randomized trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: a novel study. Eur. J. Clin. Invest. 33, 824-829 (2003).
    • (2003) Eur. J. Clin. Invest , vol.33 , pp. 824-829
    • Ahmadi, J.1    Ahmadi, K.2    Ohaeri, J.3
  • 150
    • 0347927456 scopus 로고    scopus 로고
    • Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France
    • Vidal-Trecan G, Varescon I, Nabet N, Boissonnas A. Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend. 69, 175-181 (2003).
    • (2003) Drug Alcohol Depend , vol.69 , pp. 175-181
    • Vidal-Trecan, G.1    Varescon, I.2    Nabet, N.3    Boissonnas, A.4
  • 151
    • 13844297152 scopus 로고    scopus 로고
    • Buprenorphine diversion and injection in Melbourne, Australia: An emerging issue?
    • Jenkinson RA, Clark NC, Fry CL, Dobbin M. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue? Addiction 100, 197-205 (2005).
    • (2005) Addiction , vol.100 , pp. 197-205
    • Jenkinson, R.A.1    Clark, N.C.2    Fry, C.L.3    Dobbin, M.4
  • 153
    • 33748553325 scopus 로고    scopus 로고
    • A survey of buprenorphine related deaths in Singapore
    • Lai SH, Yao YJ, Lo DS. A survey of buprenorphine related deaths in Singapore. Forensic Sci. Int. 162, 80-86 (2006).
    • (2006) Forensic Sci. Int , vol.162 , pp. 80-86
    • Lai, S.H.1    Yao, Y.J.2    Lo, D.S.3
  • 154
    • 33645015850 scopus 로고    scopus 로고
    • Intravenous use of buprenorphine tablets associated with rhabdomyolysis and compressive sciatic neuropathy
    • Seet RC, Lim EC. Intravenous use of buprenorphine tablets associated with rhabdomyolysis and compressive sciatic neuropathy. Ann. Emerg. Med. 47, 396-397 (2006).
    • (2006) Ann. Emerg. Med , vol.47 , pp. 396-397
    • Seet, R.C.1    Lim, E.C.2
  • 156
    • 33845419520 scopus 로고    scopus 로고
    • Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine
    • McCance-Katz E, Moody DE, Morse GD et al. Interactions between buprenorphine and antiretrovirals. I. The nonnucleoside reverse-transcriptase inhibitors efavirenz and delavirdine. Clin. Infect. Dis. 43, S224-S234 (2006).
    • (2006) Clin. Infect. Dis , vol.43
    • McCance-Katz, E.1    Moody, D.E.2    Morse, G.D.3
  • 157
    • 33845416796 scopus 로고    scopus 로고
    • Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir
    • McCance-Katz EF, Moody DE, Smith PF et al. Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. Clin. Infect. Dis. 43(Suppl. 4), S235-S246 (2006).
    • (2006) Clin. Infect. Dis , vol.43 , Issue.SUPPL. 4
    • McCance-Katz, E.F.1    Moody, D.E.2    Smith, P.F.3
  • 158
    • 33646805000 scopus 로고    scopus 로고
    • Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir
    • Bruce RD, Altice FL. Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir. AIDS 20, 783-784 (2006).
    • (2006) AIDS , vol.20 , pp. 783-784
    • Bruce, R.D.1    Altice, F.L.2
  • 160
    • 0030984837 scopus 로고    scopus 로고
    • Metabolism of phencyclidine by human liver microsomes
    • Laurenzana EM, Owens SM. Metabolism of phencyclidine by human liver microsomes. Drug Metab. Dispos. 25, 557-563 (1997).
    • (1997) Drug Metab. Dispos , vol.25 , pp. 557-563
    • Laurenzana, E.M.1    Owens, S.M.2
  • 161
    • 33344475261 scopus 로고    scopus 로고
    • Selective pathways for the metabolism of phencyclidine by cytochrome p440 2b enzymes: Identification of electrophilic metabolites, glutathione, and N-acetyl cysteine adducts
    • Shebley M, Jushchyshyn MI, Hollenberg PF. Selective pathways for the metabolism of phencyclidine by cytochrome p440 2b enzymes: identification of electrophilic metabolites, glutathione, and N-acetyl cysteine adducts. Drug Metab. Dispos. 34, 375-383 (2006).
    • (2006) Drug Metab. Dispos , vol.34 , pp. 375-383
    • Shebley, M.1    Jushchyshyn, M.I.2    Hollenberg, P.F.3
  • 162
    • 0026586613 scopus 로고
    • Human hepatic microsomal metabolism of δ 1-tetrahydrocannabinol
    • Bornheim LM, Lasker JM, Raucy JL. Human hepatic microsomal metabolism of δ 1-tetrahydrocannabinol. Drug Metab. Dispos. 20, 241-246 (1992).
    • (1992) Drug Metab. Dispos , vol.20 , pp. 241-246
    • Bornheim, L.M.1    Lasker, J.M.2    Raucy, J.L.3
  • 163
    • 0029114516 scopus 로고
    • Involvement of CYP2C in the metabolism of cannabinoids by human hepatic microsomes from an old woman
    • Watanabe K, Matsunaga T, Yamamoto I, Funae Y, Yoshimura H. Involvement of CYP2C in the metabolism of cannabinoids by human hepatic microsomes from an old woman. Biol. Pharm. Bull. 18, 1138-1141 (1995).
    • (1995) Biol. Pharm. Bull , vol.18 , pp. 1138-1141
    • Watanabe, K.1    Matsunaga, T.2    Yamamoto, I.3    Funae, Y.4    Yoshimura, H.5
  • 164
    • 24344435153 scopus 로고    scopus 로고
    • CYP2C-catalyzed δ9-tetrahydrocannabinol metabolism: Kinetics, pharmacogenetics and interaction with phenytoin
    • Bland TM, Haining RL, Tracy TS, Callery PS. CYP2C-catalyzed δ9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. Biochem. Pharmacol. 70, 1096-1103 (2005).
    • (2005) Biochem. Pharmacol , vol.70 , pp. 1096-1103
    • Bland, T.M.1    Haining, R.L.2    Tracy, T.S.3    Callery, P.S.4
  • 165
    • 33847633815 scopus 로고    scopus 로고
    • Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes
    • Watanabe K, Yamaori S, Funahashi T, Kimura T, Yamamoto I. Cytochrome P450 enzymes involved in the metabolism of tetrahydrocannabinols and cannabinol by human hepatic microsomes. Life Sci. 80, 1415-1419 (2007).
    • (2007) Life Sci , vol.80 , pp. 1415-1419
    • Watanabe, K.1    Yamaori, S.2    Funahashi, T.3    Kimura, T.4    Yamamoto, I.5
  • 166
    • 0037040369 scopus 로고    scopus 로고
    • The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir
    • Kosel BW, Aweeka FT, Benowitz NL et al. The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS 16, 543-550 (2002).
    • (2002) AIDS , vol.16 , pp. 543-550
    • Kosel, B.W.1    Aweeka, F.T.2    Benowitz, N.L.3
  • 167
    • 21344472982 scopus 로고    scopus 로고
    • Hezode C, Roudot-Thoraval F, Nguyen S et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. [Erratum appears in Hepatology 42(2), 506]. Hepatology (2005) 42, 63-71 (2005).
    • Hezode C, Roudot-Thoraval F, Nguyen S et al. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. [Erratum appears in Hepatology 42(2), 506]. Hepatology (2005) 42, 63-71 (2005).
  • 168
    • 34248174783 scopus 로고    scopus 로고
    • Primary behavioral prevention of HIV transmission: Tested strategies
    • In Press
    • Altice F, Safren S, Wingood G. Primary behavioral prevention of HIV transmission: tested strategies. Clin. Infect. Dis. (2007) (In Press).
    • (2007) Clin. Infect. Dis
    • Altice, F.1    Safren, S.2    Wingood, G.3
  • 169
    • 33845403539 scopus 로고    scopus 로고
    • The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention
    • Altice FL, Sullivan LE, Smith-Rohrberg D, Basu S, Stancliff S, Eldred L. The potential role of buprenorphine in the treatment of opioid dependence in HIV-infected individuals and in HIV infection prevention. Clin. Infect. Dis. 43(Suppl. 4), S178-S183 (2006).
    • (2006) Clin. Infect. Dis , vol.43 , Issue.SUPPL. 4
    • Altice, F.L.1    Sullivan, L.E.2    Smith-Rohrberg, D.3    Basu, S.4    Stancliff, S.5    Eldred, L.6
  • 170
    • 28944443527 scopus 로고    scopus 로고
    • Clinician-delivered intervention during routine clinical care reduces unprotected sexual behavior among HIV-infected patients
    • Fisher JD, Fisher WA, Cornman DH, Amico RK, Bryan A, Friedland GH. Clinician-delivered intervention during routine clinical care reduces unprotected sexual behavior among HIV-infected patients. J. Acquir. Immune Defic. Syndr. 41, 44-52 (2006).
    • (2006) J. Acquir. Immune Defic. Syndr , vol.41 , pp. 44-52
    • Fisher, J.D.1    Fisher, W.A.2    Cornman, D.H.3    Amico, R.K.4    Bryan, A.5    Friedland, G.H.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.